Who Should Be Monitored for Tysabri-Related PML?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Assessment

If you or a loved one is taking Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is crucial. This rare but serious brain infection has been the subject of extensive pharmacovigilance research over the past two decades, establishing a clear link between treatment duration, JC virus antibody status, and PML risk. This page outlines key risk factors to review with your healthcare provider.

Clinical Presentation and Diagnosis of PML

PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The condition results from reactivation of JC virus (JCV), which infects oligodendrocytes and causes progressive demyelination. Early symptoms may include cognitive changes, motor deficits, visual disturbances, or seizures. Diagnosis relies on MRI imaging showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction. Because PML can mimic MS relapses, prompt evaluation is critical. The FDA label instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Tysabri Pharmacology and Reported Adverse Effects

Tysabri is a monoclonal antibody that binds to alpha-4 integrin, blocking lymphocyte adhesion and migration into the central nervous system. This mechanism reduces inflammatory activity in MS but also impairs immune surveillance against JCV in the brain. In clinical trials, PML occurred in three patients who received Tysabri. Two cases were observed among 1869 MS patients treated for a median of 120 weeks; both had received Tysabri in addition to interferon beta-1a. The third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These data underscore that PML risk is present even with monotherapy and can emerge within the first year of treatment.

Mechanistic Pathways Linking Tysabri to PML

The mechanistic link between Tysabri and PML involves reduced immune surveillance. By inhibiting lymphocyte trafficking into the brain, Tysabri diminishes the ability of the immune system to control JCV replication. The virus, which is latent in many individuals, can then reactivate and cause lytic infection of oligodendrocytes. Three established risk factors for PML in Tysabri-treated patients are: the presence of anti-JCV antibodies (indicating prior exposure to the virus), longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Legal Implications

The FDA label includes a boxed warning stating that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning identifies the three risk factors and advises that they should be weighed against expected benefit. It also mandates that Tysabri be withheld immediately at the first sign or symptom suggestive of PML. Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). While these warnings are explicit, questions may arise regarding whether prescribers and patients fully understand the magnitude of risk, particularly in patients with multiple risk factors. The label also notes that in Crohn's disease, Tysabri should not be used in combination with immunosuppressants or TNF-alpha inhibitors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), which may be relevant to risk mitigation.

Attorney-Related Considerations for Affected Patients

For patients who develop PML after Tysabri treatment, legal considerations may include whether the manufacturer provided adequate warnings about the risk and whether the patient's specific risk factors were properly assessed. The boxed warning and restricted distribution program indicate that the manufacturer has taken steps to communicate risk, but individual cases may involve allegations of failure to warn or inadequate monitoring. Patients should document the timeline of Tysabri exposure, any prior immunosuppressant use, and the date of PML diagnosis. Legal counsel may review whether anti-JCV antibody testing was performed and whether treatment duration exceeded two years. The settlement criteria for Tysabri PML lawsuits typically involve factors such as the severity of disability, the presence of multiple risk factors, and the adequacy of informed consent.

Timeline Between Exposure and Documented Harm

The latency between starting Tysabri and PML diagnosis varies. In clinical trials, one case occurred after eight doses (approximately two months) in a Crohn's disease patient, while two MS cases occurred after a median of 120 weeks (about 2.3 years) of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label identifies longer treatment duration, especially beyond two years, as a risk factor (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This suggests that while PML can occur early, the risk accumulates with continued exposure. Patients who develop PML after prolonged therapy may have stronger grounds for legal claims if they were not adequately monitored or warned about the increasing risk over time.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and why is it associated with PML?

Tysabri (natalizumab) is a biologic therapy approved for relapsing forms of multiple sclerosis and Crohn's disease. It works by blocking immune cell migration into the brain, which reduces inflammation but also impairs immune surveillance against the JC virus, increasing the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the settlement criteria for Tysabri PML lawsuits?

Settlement criteria typically include documented Tysabri exposure, confirmed PML diagnosis, severity of disability, presence of multiple risk factors (e.g., anti-JCV antibodies, treatment duration >2 years, prior immunosuppressant use), and evidence of inadequate warnings or monitoring. Each case is evaluated individually.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Label for Tysabri

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.